Locations:
SearchLearn about featured clinical trials currently enrolling or search our trials database
Phase 2, Open-Label, Imaging Trial of I-124-CLR1404 in Patients with Newly Diagnosed or Recurrent Glioblastoma
CLTR 1314 | 14-483
Disease(s): Brain, Glioblastoma
See full trial information
Advertisement
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy
A Phase III, Open Label, Randomised, Controlled, Multi-centre Study to assess the efficacy and safety of Olaparib Monotherapy versus Physician’s Choice Chemotherapy in the Treatment of Metastatic Breast Cancer Patients with germline BRCA1/2 Mutations
ZNCA 1114 | 14-656
Disease(s): Breast cancer
See full trial information
Safety, efficacy, tolerability, pharmacokinetics and pharmacodynamics of open-label study with multiple and (for non-responders) escalating subcutaneous doses of BI 655064 once a week in patients with chronic primary immune thrombocytopenic purpura
BIP 1Z14 | 15-042
Disease: Chronic Immune Thrombocytopenic Purpura
See full trial information
A Phase 1, Multicenter, Open-Label, Dose-Escalation and Expansion, Safety, Pharmacokinetic, Pharmacodynamic, and Clinical Activity Study of Orally Administered AG-221 in Subjects with Advanced Hematologic Malignancies with an IDH2 Mutation
AGSP 1Z14 | 15-124
Disease: Hematologic Malignancy, Leukemia, Acute Myeloid (AML), Myelodysplastic Syndrome (MDS)
See full trial information
A phase 1b dose-escalation study of SGN-CD33A in combination with standard-of-care for patients with newly diagnosed acute myeloid leukemia (AML)
SEGE 1914 | 15-144
Disease(s): Leukemia, Acute Myeloid (AML)
See full trial information
A Phase 2b Open-label, Randomized Two-arm Study of Selinexor (KPT-330) with Low Dose Dexamethasone in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
KARY 1414 | 14-1340
Disease: Lymphoma
See full trial information
Advertisement
A Phase II, Open-label, Multicenter, Randomized Study of CDX-1401, a Dendritic Cell Targeting NY-ESO-1 Vaccine, in Patients with Malignant Melanoma Pre-Treated with Recombinant CDX-301, a Recombinant Human Flt3 Ligand
NCI 1615 | 15-119
Disease(s): Melanoma
See full trial information
A Phase 3, Study of Momelotinib Versus Best Available Therapy in Anemic or Thrombocytopenic Subjects with Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, or Post-essential Thrombocythemia Myelofibrosis who were Treated with Ruxolitinib
GSI 3Z14 | 15-048
Disease(s): Myelofibrosis
See full trial information
A Phase I/II, Multicenter, Open-label, Dose Escalation and Randomized Trial of BI 836858 in Patients with Low or Intermediate-1 Risk Myelodysplastic Syndromes
BIP 1914 | 14-1163
Disease(s): Myelodysplastic Syndrome (MDS)
See full trial information
A Phase 2, double-blind, randomized safety and efficacy study of PF-04449913 versus placebo with defined best supportive therapy allowed in both arms in patients with Myelofibrosis previously treated with one or more Janus kinase inhibitors
PFIZ 1Z14 | 14-1326
Disease: Myelofibrosis
See full trial information
TIGER-2: A Phase 2, Open-Label, Multicenter, Safety and Efficacy Study of Oral CO-1686 as 2nd Line EGFR-Directed TKI in Patients with Mutant EGFR Non-Small Cell Lung Cancer (NSCLC) with the T790M Resistance Mutation
CLVS 1514 | 14-775
Disease(s): Non-small cell lung cancer (NSCLC)
See full trial information
Advertisement
Advertisement
First-of-its-kind research investigates the viability of standard screening to reduce the burden of late-stage cancer diagnoses
Global R&D efforts expanding first-line and relapse therapy options for patients
Study demonstrates ability to reduce patients’ reliance on phlebotomies to stabilize hematocrit levels
A case study on the value of access to novel therapies through clinical trials
Findings highlight an association between obesity and an increased incidence of moderate-severe disease
Cleveland Clinic Cancer Institute takes multi-faceted approach to increasing clinical trial access 23456
Key learnings from DESTINY trials
Overall survival in patients treated since 2008 is nearly 20% higher than in earlier patients